Personalis, Inc. to Present at IO Combinations 360˚
02 10월 2020 - 2:20AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for cancer, today announced the company’s participation at IO
Combinations 360˚ which will be held online, October 1-2, 2020.
The presentation, titled “Comprehensive immunogenomics to enable
composite biomarkers for immunotherapy response using a sample
sparing approach,” will describe the Personalis universal cancer
immunogenomics platform, ImmunoID NeXT™. Travis Yates, PhD, will
present for Personalis.
Dr. Yates will discuss the benefits of this unique, innovative
design for immuno-oncology translational research, including
mastering challenging samples, utilizing optimized algorithms, and
obtaining accurate genomic data for identifying novel predictors of
response. He will review a case study from a cohort of metastatic
melanoma patients treated with an immune checkpoint blockade and
will highlight the analytical capabilities provided by this
immunogenomic profiling solution for understanding mechanisms of
tumor evasion and creating composite biomarkers. Additionally, he
will introduce NeXT Liquid Biopsy™, an exome-wide liquid biopsy
approach combined with ImmunoID NeXT, to further explore critical
areas of tumor biology.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veteran Program (VA MVP). In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform, Personalis’ services for the VA MVP,
the company’s business opportunities, leadership or growth, or
other future events. Such forward-looking statements involve risks
and uncertainties, including those related to the COVID-19
pandemic, that could cause actual results to differ materially from
any anticipated results or expectations expressed or implied by
such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including the company’s most
recent reports on Forms 8-K, 10-K and 10-Q, and include those
listed under the caption “Risk Factors.” Personalis disclaims any
obligation to update such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201001005978/en/
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024